GlassScriptPhysician profile
Donald Keith Cobb
NPI 1386688554
$3,491.01
in general payments reported to CMS, 2019-2025
29 companies · $1,166 in 2025
The $1,166 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $263 · 2021: $271 · 2022: $321 · 2023: $410 · 2024: $883 · 2025: $1,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,458.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $753.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $416.72 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $416.09 | 2022-2025 | Ubrelvy, Qulipta, Viberzi |
| Amgen INC. | $208.13 | 2019-2025 | Repatha, Otezla, Evenity |
| Astellas Pharma US INC | $195.44 | 2019-2025 | Veozah |
| Pfizer INC. | $187.55 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $184.11 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Esperion Therapeutics, INC. | $158.45 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.23 | 2020-2025 | Jardiance, Ofev |
| Idorsia Pharmaceuticals US INC | $91.73 | 2023-2024 | Quviviq |
| Glaxosmithkline, LLC. | $90.40 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Sunovion Pharmaceuticals INC. | $83.71 | 2019-2020 | |
| Dexcom, INC. | $68.68 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $57.72 | 2020-2025 | Gardasil 9, Gardasil, Capvaxive |
| Antares Pharma, INC. | $55.30 | 2025 | Xyosted |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $53.77 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.44 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.04 | 2025 | Xifaxan |
| Genentech USA, INC. | $31.53 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $30.48 | 2021 | |
| Exact Sciences Corporation | $29.22 | 2023-2024 | Cologuard Collection Kit |
| Paratek Pharmaceuticals, INC. | $29.15 | 2023-2024 | Nuzyra |
| Biohaven Pharmaceutical Holding Company LTD. | $23.24 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.28 | 2024 | Caplyta |
| Inspire Medical Systems, INC. | $19.68 | 2025 | Inspire |
| Phathom Pharmaceuticals, INC. | $18.41 | 2024 | Voquezna |
| Ultragenyx Pharmaceutical INC. | $18.40 | 2023 | |
| Janssen Pharmaceuticals, INC | $15.98 | 2024 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $13.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Cobb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.